"IDX375 (the non-nuke) and IDX316 (the PI) have activity against genotypes 1a and 1b. I’m not aware of claims that they have activity against other HCV genotypes"
the idenix PIs are highly active against gen-4 (the other difficult to treat genotype) with an IC50 comparable to gen-1. In addition to the much higher potency compared to telaprevir (all the idix compounds it seems are being designed with an eye towards coformulation), this is a major distinguishing feature from telaprevir
note both telaprievir and idx316 are also active, albeit less so, against gen-2. they have no activity against gen-3